COMP <GO>
IMRN vs CNSP // REVENUE GROWTH (YOY)
Immuron Limited (NASDAQ) VS. CNS Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: IMRN 1
— CNSP 1
■ METRIC PARITY
LAST: $0.92 (+2.48%) • MKT CAP: $7.4M
revenue-growth
—
LAST: $4.77 (+5.77%) • MKT CAP: $7.0M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMRN VS. CNSP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IMRN | CNSP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 1/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.0 | 48.9 | -16.83 | CNSP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.4M | $7.0M | $473.8K | IMRN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IMRN REV | CNSP REV | IMRN GROSS % | CNSP GROSS % | IMRN FCF | CNSP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $0 | — | — | — | -$13.8M |
| FY 2024 | — | $0 | — | — | — | -$17.1M |
| FY 2023 | — | $0 | — | — | — | -$14.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMRN // BETA —
CNSP // BETA —